Holen Sie sich die Stockscreener-App
1.5573
0.47%
0.0073
Schlusskurs vom Vortag:
$1.55
Offen:
$1.58
24-Stunden-Volumen:
30,857
Relative Volume:
0.27
Marktkapitalisierung:
$18.27M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-3.15M
KGV:
-5.1026
EPS:
-0.3052
Netto-Cashflow:
$-2.23M
1W Leistung:
-11.01%
1M Leistung:
-20.14%
6M Leistung:
-24.03%
1J Leistung:
-43.37%
1-Tages-Spanne:
$1.50
$1.72
1-Wochen-Bereich:
$1.50
$2.12
52-Wochen-Spanne:
$1.50
$4.0499
Cytomed Therapeutics Ltd Stock (GDTC) Company Profile
Firmenname
Cytomed Therapeutics Ltd
Sektor
Branche
Telefon
-
Adresse
-
Vergleichen Sie GDTC mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GDTC
Cytomed Therapeutics Ltd
|
1.5573 | 18.19M | 0 | -3.15M | -2.23M | -0.3052 |
|
VRTX
Vertex Pharmaceuticals Inc
|
444.64 | 110.88B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
726.21 | 72.79B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
890.11 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
404.46 | 54.85B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
189.85 | 41.41B | 447.02M | -1.18B | -906.14M | -6.1812 |
Cytomed Therapeutics Ltd Aktie (GDTC) Neueste Nachrichten
CytoMed stock jumps after announcing clinical trial partnership in Malaysia By Investing.com - Investing.com South Africa
CytoMed stock jumps after announcing clinical trial partnership in Malaysia - Investing.com India
CytoMed Therapeutics enters clinical trial agreement with Malaysian hospital - Investing.com
CytoMed Therapeutics (NASDAQ: GDTC) plans first-in-human gamma delta T cell trial in Malaysia - Stock Titan
CytoMed Therapeutics (NASDAQ: GDTC) to run first-in-human Malaysia trial of donor-derived γδ T cells - Stock Titan
CytoMed Therapeutics (GDTC) Stock Analysis Report | Financials & Insights - Benzinga
Why CytoMed Therapeutics Limited (F98) stock appears on watchlists2025 Price Momentum & Reliable Trade Execution Plans - Newser
Will CytoMed Therapeutics Limited (F98) stock benefit from Fed rate cuts2025 Short Interest & Intraday High Probability Setup Alerts - Newser
CytoMed acquires T Cell technology from UK to treat cancers in China and India - BioSpectrum Asia
CytoMed Therapeutics acquires T Cell technology from UK to treat cancers in China and India - BioSpectrum Asia
Applying Wyckoff theory to CytoMed Therapeutics Limited stock2025 Trade Ideas & Weekly Hot Stock Watchlists - newser.com
What earnings margins imply for CytoMed Therapeutics Limited (F98) stockQuarterly Trade Review & AI Driven Stock Movement Reports - newser.com
How CytoMed Therapeutics Limited stock reacts to job market dataPortfolio Update Summary & Daily Technical Stock Forecast Reports - newser.com
Can you recover from losses in CytoMed Therapeutics LimitedTrade Risk Report & AI Driven Stock Reports - newser.com
CytoMed Therapeutics Ltd (GDTC) can make a big difference with a little luck - Setenews
Will CytoMed Therapeutics Limited stock outperform Dow Jones indexJuly 2025 Short Interest & Entry Point Confirmation Alerts - newser.com
Why CytoMed Therapeutics Limited stock remains a top recommendationWatch List & Safe Entry Point Identification - newser.com
CytoMed acquires TC BioPharm’s gamma delta T cell technology By Investing.com - Investing.com Canada
How dovish Fed policy supports CytoMed Therapeutics Limited (F98) stock - newser.com
Can CytoMed Therapeutics Limited (F98) stock resist broad market declinesMarket Risk Summary & Daily Profit Focused Stock Screening - newser.com
What insider trading reveals about CytoMed Therapeutics Limited stockQuarterly Trade Review & High Win Rate Trade Tips - newser.com
Will CytoMed Therapeutics Limited (F98) stock maintain strong growthProduct Launch & Stepwise Trade Signal Implementation - newser.com
CytoMed acquires TC BioPharm's gamma delta T cell technology By Investing.com - Investing.com Nigeria
[6-K] CytoMed Therapeutics Ltd Current Report (Foreign Issuer) | GDTC SEC FilingForm 6-K - Stock Titan
Royal Caribbean (NYSE: RCL) launches unsecured notes sale to finance Celebrity Xcel - Stock Titan
Is CytoMed Therapeutics Limited (F98) stock a fit for income portfoliosMarket Risk Summary & Free Low Drawdown Momentum Trade Ideas - newser.com
Will CytoMed Therapeutics Limited (F98) stock keep high P E multiples2025 Key Lessons & Weekly Top Stock Performers List - newser.com
Is a relief rally coming for CytoMed Therapeutics Limited holdersMarket Activity Summary & Fast Gain Swing Alerts - newser.com
CytoMed Therapeutics Limited recovery potential after sell offJuly 2025 Highlights & Free Low Drawdown Momentum Trade Ideas - newser.com
Is CytoMed Therapeutics Limited (F98) stock undervalued historically2025 Market Outlook & Risk Managed Investment Signals - newser.com
How to monitor CytoMed Therapeutics Limited with trend dashboardsJuly 2025 Weekly Recap & Safe Swing Trade Setups - newser.com
Is CytoMed Therapeutics Limited stock attractive for income investorsMarket Risk Summary & Community Consensus Picks - newser.com
Is CytoMed Therapeutics Limited stock vulnerable to regulatory risksJuly 2025 Momentum & Technical Pattern Based Signals - newser.com
GDTC Stock Institutional Owners - Quiver Quantitative
CytoMed Therapeutics Limited (GDTC) Stock Price, News, Quote & History - Yahoo! Finance Canada
There is no way CytoMed Therapeutics Ltd (GDTC) can keep these numbers up - setenews.com
CytoMed Therapeutics secures $500,000 investment for subsidiary By Investing.com - Investing.com Nigeria
CytoMed Therapeutics Secures Non-Dilutive Investment for Subsidiary LongevityBank from ICH Capital and Updates on New China Strategy - The Manila Times
CytoMed Therapeutics Secures Non-Dilutive Investment for - GlobeNewswire
Valuation Update: Is CytoMed Therapeutics Limited stock vulnerable to regulatory risks2025 Retail Activity & Free Growth Oriented Trading Recommendations - Fundação Cultural do Pará
CytoMed Therapeutics Limited stock trend outlook and recovery path2025 Technical Overview & Safe Capital Growth Stock Tips - newser.com
Finanzdaten der Cytomed Therapeutics Ltd-Aktie (GDTC)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.45%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):